Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michael F Holick, PhD,MD
Boston University
Principal Investigator - Mohamadali Sahraian, MD
Multiple Sclerosis Research Center, Tehran University of Medical Sciences
Study Chair - Zhila Maghbooli, PhD
Multiple Sclerosis Research Center, Tehran University of Medical Sciences
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2022
- Primary completion
- 30 Jun 2023
- Completion
- 31 Dec 2023
- Last update posted
- 22 Apr 2022
- Registered enrollment
- 54
- Registry id
- NCT05340985
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 30 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.